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A new way to combat a deadly form of 
leukemia—acute lymphoblastic 
leukemia—may be emerging from 
studies of an experimental drug to 
combat acquired immune deficiency 
syndrome (AIDS). The studies are being 
conducted by Humphrey Cancer 
Research Center member Ronald 
McCaffrey, M.D., and his associates at 
the University Hospital, a principal 
teaching affiliate of Boston University 
School of Medicine. 
During research on the anti-AIDS 
agent dideoxyadenosine (ddA), a medical 
resident working with Dr. McCaffrey 
observed that the drug killed cultures of 
certain types of acute leukemia cells. 
"This killing effect of ddA potentially 
holds great promise for leukemia 
patients," says Dr. McCaffrey, who heads 
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Cholesterol: 
A new weapon 
against cancer? 
For years, physicians have advised 
patients to cut down on cholesterol in 
their diets in order to lower their blood 
cholesterol levels and, consequently, their 
risk of clogged coronary arteries. 
However, studies have shown that low 
cholesterol levels sometimes are 
associated with the development of bowel 
cancer, according to Selwyn A. Broitman, 
Ph.D., a researcher at the Hubert 
Humphrey Cancer Research Center and a 
professor of microbiology at Boston 
University School of Medicine. In 
studying this dilemma. Dr. Broitman and 
his associates may have discovered a way 
to use the tumor cells' need for 
cholesterol to control the spread of this 
prevalent form of cancer. 
Ten years ago. Dr. Broitman noticed 
that when laboratory animals with high 
cholesterol levels were put on 
low-cholesterol diets, their cholesterol 
levels fell, but they also developed many 
more bowel tumors than animals fed 
normal diets. Similarly, epidemiologists 
at the Boston University-Framingham 
Heart Study found that people with 
cholesterol levels below what is 
considered normal (below 180 milligrams 
percent in the blood) were four to five 
times as likely to develop bowel cancer as 
people with above-normal cholesterol 
levels (above 220 milligrams percent). 
According to the researcher, people 
from countries with diets rich in fat and 
cholesterol show a high incidence of both 
coronary artery disease and bowel cancer. 
"However, an analysis of these 
continued on page 2 
Ronald McCaffrey, M.D., right, and Zachary Spigelman, M.D., have discovered that a drug used 
to combat AIDS also appears to kill certain leukemia cells. (Photo by David Keough) 
Humphrey Center researcher finds anti-AIDS 
drug may benefit some leukemia patients 
the UH Section of Medical Oncology and 
is a professor of medicine at the School. 
"However, its effect on leukemia cells is 
distinct from its anti-AIDS action." 
Such compounds as ddA and AZT 
(the only anti-AIDS drug currently 
approved by the federal Food and Drug 
Administration) are chemical variants 
(analogues) of natural substances used by 
cells to build DNA, the genetic material 
needed for cells to reproduce, explains 
Dr. McCaffrey. In the case of AIDS, the 
virus mistakes AZT for the natural 
substance thymidine. The use of AZT 
instead of thymidine stops the synthesis 
of DNA and the virus is unable to 
reproduce. 
"Our question was: Are there any 
other enzymes that can be fooled in the 
continued on page 3 
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Cholesterol 
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populations reveals that a certain number 
of people with high cholesterol levels 
develop heart disease, while another 
proportion, who do not have high 
cholesterol levels, develop bowel cancer," 
says Dr. Broitman. "Instead, their 
cholesterol somehow gets shunted out 
through the large bowel and contributes to 
the development of bowel cancer." 
He is quick to point out that an 
increased risk of bowel cancer is 
associated only with-abnormally low 
levels of cholesterol—in other words, 
under the 180mg percent in the blood. 
"Reducing cholesterol levels from 250 
to 200mgs, for example, by a combination 
of diet and drugs, probably is good for 
your heart and is not likely to increase the 
risk of colon cancer," he explains. 
Still the question remains: Why would 
low levels of cholesterol be associated 
with bowel cancer at all? 
Dr. Broitman and his associates have 
worked with bowel tumors in rats and 
found that these tumors actively absorb 
cholesterol from the blood, much more 
than normal, noncancerous tissue. When 
these experiments were repeated with 
human bowel cancer cells, however, the 
researchers found that none of the cancer 
cells picked up cholesterol. 
Dr. Broitman and postdoctoral student 
Michelle Eabricant, Ph.D., reasoned that 
possibly the human tumor cells did not 
pick up cholesterol because they lacked 
low density lipoprotein (LDL) receptors 
on their surfaces. (UDL is the form in 
which cholesterol gets ferried from the 
blood into cells.) 
"Many types of cells and tissues— 
liver, adrenal glands, avarie^ fibroblasts 
(the cells that cause scars)—have LDL 
receptors that can trap cholesterol for 
their use. These cells do not have to 
make cholesterol themselves but can 
extract it ready-made from the 
bloodstream," explains Dr. Broitman. 
In fact. Dr. Eabricant was able to show 
that none of the human tumor cell lines 
studied had LDL receptors. This led to 
the conclusion that i f tumors were unable 
to use cholesterol from the blood, and 
therefore had to manufacture it 
themselves, it might be possible to 
destroy tumor cells by cutting off their 
internal synthesis of cholesterol. 
"This was a very important finding for 
us," says Dr. Broitman. "Al l cells have to 
make some cholesterol, as structural 
components for their membranes and 
Selwyn Broitman, Ph.D., left, is studying how a number of fats, including cholesterol, affect the 
development of bowel cancer. lRe~discusses his research with technician Wells Wilkinson and 
M.D. - Ph.D. student Frank Cannizzo. (Photo by Bradford F. Herzog) 
other cell products, and there now is 
available a variety of drugs that can stop 
this synthesis. One is Lovastatin, 
recently licensed by the Food and Drug 
Administration to lower blood 
cholesterol levels." Lovastatin causes the 
liver to stop making cholesterol and 
begin using cholesterol available in the 
bloodstream. 
Drs. Broitman and Eabricant have 
shown that tumor cells given Lovastatin 
do indeed die as a result. On the other 
hand, when Lovastatin was given to 
normal, noncancerous cells, these cells 
sprouted LDL receptors and started to 
take it in from the blood to get around the 
drug block. 
According to Dr. Broitman, i f a bowel 
tumor has spread (metastasized) to the 
liver, where the drug is concentrated, the 
nevA tumor might be controlled by giving 
the patient Lovastatin. The drug would 
prevent the new tumor from growing but 
not injure the healthy liver cells. 
"This could be a relatively benign 
procedure for controlling metastatic 
lesions," he says. Fifty percent or more 
of people who undergo surgery for bowel 
cancer ultimately have metastatic lesions. 
Dr. Broitman, hopes to begin patient 
trials of Lovastatin soon. He and his 
research group also are looking at other 
types of tumors for the presence or 
absence of LDL receptors, which might 
render the cancers susceptible to similar 
control. 
"It is not yet known whether other 
tumors, such as breast tumors, also lack 
LDL receptors. We are just beginning to 
look into it," he says. 
QUESTIONS... 
Answer to question on back panel. 
Studies have shown that the 
chances of developing colon, breast, 
prostate, gallbladder, ovarian and uterine 
cancers all are increased for people who 
are 40 percent or more overweight. But 
the cancer risks associated with obesity 
are really an extension of the cancer risks 
of high-fat, high-cholesterol diets in 
general. 
Fat acts as a cancer promoter, 
shortening the amount of time it takes a 
carcinogen (such as cigarette smoke) to 
transform a normal cell into a cancerous 
one. All of us may have some cells 
transfonried by a caix:inoj.em but the _ 
process is so slow we are more likely to 
die of old age or other causes before the 
cancer becomes evident. In the presence 
of a promoter, this cancerous transfor-
mation of cells is accelerated and the 
tumor manifests itself much sooner. 
It is not yet clear how fat acts as a 
promoter. Some researchers suggest it is 
a nutrient for cancer cells, others believe 
it acts as an oxidative agent that 
interferes with normal cell functioning. 
While research in this area has a long 
way to go, it is clear that by reducing the 
total amount of fat in your diet, you can 
reduce your risk of developing certain 
cancers. 
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Leukemia 
continued from page 1 
same way," says Dr. McCaffrey, whose 
laboratory does research on the enzymes 
that put together and take apart DNA. 
As part of an AIDS research project, 
the National Cancer Institute (NCI) in 
Washington, D.C., asked Dr. McCaffrey 
and medical resident Zachary Spigelman, 
M.D., to test a number of analogues 
against a variety of DN A-making 
enzymes and assess how readily an 
enzyme accepted an analogue in place of 
the natural substance. 
"To do a comprehensive study we 
included an enzyme called TdT, which is 
found in some acute leukemia cells," 
says Dr. McCaffrey, who discovered 
TdT some 17 years earlier while working 
at the Massachusetts Institute of 
Technology. For years, scientists have 
been puzzled as to the function of this 
enzyme and, until now, did not know 
whether it controlled any vital process in 
leukemia cells. 
The researchers were surprised to find 
that TdT could and did use ddA instead 
of natural DNA building blocks. As a 
result, all DNA building was stopped. 
According to Dr. McCaffrey, when ddA 
vas introduced into cultures of leukemia 
cells, those cells that contained the TdT 
enzyme were killed within 72 hours. 
The same killing effect was seen in fresh 
leukemia cells taken from newly 
diagnosed patients, he says. 
Drs. McCaffrey and Spigelman 
determined that the killing of leukemia 
cells by ddA was due to the presence of 
TdT within the cells. The analogue 
interacts with TdT in such a way that the 
DNA of the cells is broken into frag-
ments and the cells die. "Essentially, 
TdT is fooled by ddA in the same way a 
different enzyme in the AIDS virus is 
fooled by AZT," explains Dr. McCaffrey. 
TdT is found in acute lymphoblastic 
leukemia cells; the other form of acute 
leukemia, called acute myeloblastic 
leukemia, does not contain TdT. As a 
result, ddA had no effect on cells of this 
form of leukemia. Acute lymphoblastic 
leukemia accounts for nearly 90 percent 
of childhood leukemia and about 25 
percent of adult leukemia. 
According to Dr. McCaffrey, 
although nearly 70 percent of childhood 
cases of acute lymphoblastic leukemia 
can be cured with existing therapies, 
these treatments are toxic and very 
painful. 
"There is a genuine need for a new 
therapy that is more gentle," he says. 
"And there is still the 30 percent of 
children with the disease who die, not to 
mention the adult cases, which, although 
less common, nearly always are fatal. 
We think ddA, or a derivative, ultimately 
may be a new way to treat these patients." 
The hitch to using ddA as therapy for 
acute lymphoblastic leukemia immedi-
ately is the amount needed to kil l the 
leukemia cells, which is about 25 times 
higher than the amount of ddA needed to 
stop the AIDS virus. 
"We think the amount of ddA needed 
is much too high for clinical use. We 
have been trying to find a derivative that 
would be effective at smaller concen-
trations," says Dr. McCaffrey. 
In fact, the researcher has designed a 
compound that works at one-hundredth 
the dose of ddA. "Although the data are 
still preliminary, the results look 
promising and the NCI is fast-tracking its 
development. The intent is to get this 
into clinical patient trials as soon as 
possible," he says. 
Dr. McCaffrey credits the intensive 
AIDS research effort as a significant 
factor contributing to the observations on 
ddA and TdT. In fact, he says, the 
anti-leukemia effect could be a major 
"spinoff" of AIDS research. 
"When the public demand for 
intensified AIDS research first began," 
says Dr. McCaffrey, "it was predicted 
that findings would result that could lead 
to the treatment of other diseases, 
especially in the area of cancer. This 
anti-leukemia effect of ddA is the first 
instance of that happening." 
IN B R I E F 
Howard Koh, M.D., an assistant 
professor of dermatology and medicine at 
BUSM and an assistant professor of 
public health at the School of Public 
Health, recently received a five-year, 
$350,000 Preventive Oncology Academic 
Award from the National Cancer 
Institute. He will use the funds to 
continue his research on the early 
detection and prevention of skin cancer, 
especially malignant melanoma. 
In addition. Dr. Koh is the co-author 
of a new American Cancer Society 
brochure called "Living with Cancer: A 
Multicultural Experience." The booklet 
was produced in five languages and 
presents general cancer information and 
stories of people from various ethnic 
groups who have survived cancer. 
Elinor Levy, Ph.D., an associate 
professor of microbiology, recently 
received a new incubator and flow hood 
to be used in her research on the 
suppression of the immune system by 
retroviruses, such as the ones that cause 
AIDS and certain leukemias, and on how 
these viruses interact with the central 
nervous system. 
The equipment was purchased for 
Levy by Aid for Cancer Research, an 
organization of women from the greater 
Boston area who raise funds to support 
the fight against cancer. 
Humphrey Center member Richard Neiman, M.D.,far left, chief of the Hematopathology Section 
of the Mallory Institute of Pathology, was among cancer researchers at Boston University 
Medical Center who recently received new laboratory equipment donated by Aid for Cancer 
Research. Dr. Neiman and his associates will use the Probe-Tek Automated Southern Blot 
Analyzer to detect molecular changes in cancer cells before they can be recognized by routine 
immunologic or microscopic methods. Shown with Dr. Neiman are hematopathology fellow 
George Wade, M.D., Ph.D., and Florence Litchman, chairman of the ACR presentation 
committee. (Photo by David Keough) 
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CANCER NOTES 
C A N C E R NOTE: Cancer of the colon 
and rectum is the second most prevalent 
type of cancer in this country after lung 
cancer. Three quarters of colorectal 
cancer cases can be cured if the disease 
is discovered before it spreads to other 
areas of the body. 
The American Cancer Society 
recommends three tests for the early 
detection of colorectal cancer: an annual 
digital rectal examination after age 40; 
an annual stool blood test after age 50; 
and a sigmoidoscopic examination every 
three to five years after age 50, once you 
have had two annual sigmoid exams with 
negative results. 
C A N C E R NOTE: It is estimated that 
one in 10 women eventually will develop 
breast cancer. The majority of breast 
cancers initially are found by women 
examining themselves. Although all 
lumps should be checked by a physician, 
a breast lump does not necessarily mean 
cancer. Roughly four-fifths of breast 
lumps biopsied turn out to be benign. 
C A N C E R NOTE: Fifty percent of all 
human cancers are curable today by 
surgery, radiation therapy, chemotherapy 
or a combination of these treatments. 
C A N C E R NOTE: People who smoke 
have a 10-times greater chance of 
developing cancer than people who do 
not smoke. Roughly 30 percent of cancer 
deaths are related to smoking. 
The Humphrey Cancer Center News is 
published for the Hubert H. Humphrey 
Cancer Research Center of Boston 
University School of Medicine by the 
Office of Publication Services, Boston 
University Medical Center. Humphrey 
Center Director, Herbert H. Wotiz, 
Ph.D.; Editors, Denise Maguire and 
Michael Rabin; Writer, Caroline H. 
Lupfer. "Cancer Notes" information is 
provided courtesy of the American 
Cancer Society. 
Are obesity and cancer related? 
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